Answers are grounded in this paper and cite their sources.
High-confidence evidence supports fremanezumab, galcanezumab, and onabotulinumtoxinA as effective prophylactic treatments for chronic migraine in adults, with moderate evidence for agents like topiramate and erenumab. Treatment choice should consider patient-specific factors, including response variability and side effect profiles.
No takes yet. Share an insight, caveat, or question.
Tripdatabase (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: